Navigation Links
Lenalidomide safe as single therapy for elderly CLL patients
Date:12/8/2008

SAN FRANCISCO ― The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

"Lenalidomide has a favorable toxicity profile and shows signs of activity against CLL in our phase II clinical trial to date," said study presenter Alessandra Ferrajoli, M.D., associate professor in M. D. Anderson's Department of Leukemia.

Patients start on a 5 mg dose of the drug in pill form and the dose escalates over time in 5 mg increments to a maximum of 25 mg. The median age of participants is 72. Chemo-immunotherapy therapy combinations that are effective in younger patients with CLL tend to be associated with a high rate of complications in patients older than 70, Ferrajoli said.

Of 43 patients enrolled in the study, 35 were evaluable because they had been treated for at least three months. Nineteen of these (54 percent) achieved a partial response, where the disease is diminished, 14 patients (40 percent) had stable disease and continue on therapy, and two had their CLL progress.

Lenalidomide also rapidly reduced the number of circulating lymphocytes the hallmark of the disease in the patients' blood. Ferrajoli said 47 percent achieved a blood complete response and 38 percent had at least a partial response.

Patients on the trial for at least two months were evaluated for the drug's potential side effects. Of those 39 patients, 10 (26 percent) had decreased bone marrow activity resulting in a decrease in the number of either white blood cells called neutrophils or of platelets. Three patients had infections, two had fever and one had pneumonia.

All patients registered in the study remain alive with 37 of the 43 continuing on treatment. Ferrajoli said the trial will include up to 60 patients.

Lenalidomide, a drug developed by Celgene Corp. known commercially as Revlimid, attacks both malignant cells and the cellular environment that nurtures them. The U.S. Food and Drug Administration has approved the drug for treatment of multiple myeloma and some forms of myelodysplastic syndrome.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. SurgiQuest Announces First Single Port Procedure for Uterus and Ovary Removal Using AirSeal(TM) Access System
2. Brigham and Womens Hospital Selects SinglePointe(TM) Automated Patient-Specific Medication Management Solution from Omnicell
3. Single in the City? How the Holidays Leave the Fabulous Feeling More Like Failures
4. First and Only Single Capsule Daily Rx Prenatal Vitamin With Plant-Based DHA Now Available
5. Elseviers New Imaging Consult Features In-Depth, Authoritative Information For Diagnostic and Interventional Imaging and Procedures in a Single Online Resource
6. Study Singles Out Beachgoers Skin Cancer Risk
7. Most Single Adults Not Using Condoms
8. University Of Minnesota Gives 11,538 Flu Shots Tuesday, Shattering Guinness World Record for Most Flu Shots in a Single Day
9. New Prostrates Grown From Single Stem Cell
10. HIV Can Re-Emerge From a Single Cell
11. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase Up to $18 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... ... July 19, 2017 , ... Adolfson & Peterson Construction ... Josh Christensen. As a leader in healthcare construction, AP has successfully built several ... in the Midwest with Josh now on board. , Josh brings over ...
(Date:7/18/2017)... Sherman Oaks, CA (PRWEB) , ... July 18, 2017 , ... ... and Ph.D. scientist extracted cannabis oils, announced today that at the WORLDZ Summit, taking ... Ryan will be speaking on the therapeutic benefits of medical cannabis for both pediatric ...
(Date:7/18/2017)... ... , ... An inventor from Anacortes, Wash., knows the difficulties and indignity of ... flashes, and I suffer from anxiety and vertigo on top of that," she said, ... about." INSTA-FAN meets that need. , This device enables a woman in menopause to ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... and Its Treatments during Pregnancy , studies take a closer look at maternal ... a developing baby with one study showing newer medications may be safer choices. ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... today announced a partnership with the Texas Academy of Family Physicians (TAFP) ... place October 20-22, 2017 at the Hyatt Regency Dallas in Dallas, Texas.     , ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... 2017 Endo International plc (NASDAQ: ENDP ) ... 2017.  Members of its senior management team will host a conference ... a.m. ET. The dial-in number to access the ... 509-7598, and the passcode is 45397076. Please dial in 10 minutes ... A replay of the call will be available from ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology: